Our data provide a strong preclinical rationale for clinical studies exploring these compounds as treatment for ALL, but suggest that 4E-BP1 or S6 phosphorylation may not be robust biomarkers in clinical trials of PI3K pathway inhibitors in ALL. This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.